Status:
UNKNOWN
Acetylamantadine Excretion by Cancer Patients
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
BioMark Technologies Inc.
St. Boniface Hospital
Conditions:
Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Several factors discourage the implementation of cancer screening to the population in general, which would result in earlier diagnosis and an expected improved survival. Concurrent in vivo and in vit...
Detailed Description
The study will involve the screening of volunteer patients with various types of cancer to provide a first indication of which types of cancer and at what stage of tumor burden acetylamantadine will b...
Eligibility Criteria
Inclusion
- newly diagnosed or untreated cancer (GI, lung, prostate and breast cancer)
- \-
Exclusion
- Any previous adverse reaction to Amantadine
- currently pregnant or lactating
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT02277938
Start Date
August 1 2013
End Date
December 1 2021
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Boniface Hospital
Winnipeg, Manitoba, Canada, R2H 2A6